ArticleMedical oncology (Northwood, London, England)2025
SARS-CoV-2 N protein exerts antitumor effects in NSCLC by inducing DNA damage and augmenting chemotherapeutic sensitivity.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Recently, we reported that the SARS-CoV-2 nucleocapsid (N) protein triggers DNA damage by inducing autophagic degradation of RNAi components (Dicer and XPO5) and splicing factors (SRSF3 and hnRNPA3). In this study, we found that the SARS-CoV-2 N protein synergizes with chemotherapeutics to induce DNA damage and activate the cGAS-STING pathway in NSCLC cells. Moreover, the SARS-CoV-2 N protein acts synergistically with chemotherapeutics to suppress the proliferation and colony formation of NSCLC cells. Finally, we demonstrated that the SARS-CoV-2 N protein enhances the antitumor effects of etoposide in xenograft tumor mouse model. These findings reveal a novel antitumor mechanism of the SARS-CoV-2 N protein, positioning it as a potential therapeutic agent for lung cancer patients.
Indexed as
Identifiers
40451965What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.